ERBB2 and myxofibrosarcoma: In one patient with metastatic low-grade myxofibrosarcoma and ERBB2 amplification along with positive HER2/neu immunohistochemistry, a targeted therapy with trastuzumab + pertuzumab was performed as a fifth-line treatment following heart transplantation.